Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAreyl Goff

Discussion

Loading...

Member takes

Overview

Observational analysis reveals improved IMWG response but low MRD negativity in patients after autologous stem cell transplant, indicating a need for novel therapies.

Key Points

  • Only 7% of patients achieved MRD negativity, with lenalidomide-isatuximab maintenance post-ASCT.
  • The 12-month progression-free survival was reported at 83%, suggesting promising outcomes in multiple myeloma.
  • Patients underwent a phase II trial involving lenalidomide and single-cell RNA sequencing for assessing treatment effects.
  • Early findings indicate significant treatment-emergent AEs, emphasizing the need for careful monitoring.

Cite This Study

Areyl Goff (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e013https://doi.org/10.1182/blood-2025-5758
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance2025 · 2 citations
  2. 2Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese2025
  3. 3Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation2025 · 1 citations
  4. 4Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma2025 · 1 citations
  5. 5Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025